László Rejtő

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 185 citations

Medicine, Hematology, Pharmacology +9

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia

Adrian C. Newland, Blanca Sánchez‐González, László Rejtő et al. · American Journal of Hematology · 2019 · 181 citations · Full text

Medicine, Hematology, Pharmacology +17

Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia

Éva Karászi, Katalin Jakab, László Homolya et al. · British Journal of Haematology · 2001 · 79 citations · Full text

Medicine, Oncology, Pharmacology +13

THE ASSOCIATION OF REDUCED ENDOTHELIUM DERIVED RELAXING FACTOR-NO PRODUCTION WITH ENDOTHELIAL DAMAGE AND INCREASED IN VIVO PLATELET ACTIVATION IN PATIENTS WITH DIABETES MELLITUS

Marianna Huszka, Miklós Káplár, László Rejtő et al. · Thrombosis Research · 1997 · 56 citations · Full text

Medicine, Endocrinology, Hematology +10

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

Szilvia Lovas, Gergely Varga, Péter Farkas et al. · International Journal of Hematology · 2019 · 28 citations

Medicine, Oncology, Pharmacology +16